Challenges and perspectives in obstructive sleep apnoea: Report by an ad hoc working group of the Sleep Disordered Breathing Group of the European Respiratory Society and the European Sleep Research Society

Obstructive sleep apnoea (OSA) is a major challenge for physicians and healthcare systems throughout the world. The high prevalence and the impact on daily life of OSA oblige clinicians to offer effective and acceptable treatment options. However, recent evidence has raised questions about the benefits of positive airway pressure therapy in ameliorating comorbidities. An international expert group considered the current state of knowledge based on the most relevant publications in the previous 5 years, discussed the current challenges in the field, and proposed topics for future research on epidemiology, phenotyping, underlying mechanisms, prognostic implications and optimal treatment of patients with OSA. The group concluded that a revision to the diagnostic criteria for OSA is required to include factors that reflect different clinical and pathophysiological phenotypes and relevant comorbidities (e.g. nondipping nocturnal blood pressure). Furthermore, current severity thresholds require revision to reflect factors such as the disparity in the apnoea–hypopnoea index (AHI) between polysomnography and sleep studies that do not include sleep stage measurements, in addition to the poor correlation between AHI and daytime symptoms such as sleepiness. Management decisions should be linked to the underlying phenotype and consider outcomes beyond AHI.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Reviews Source Type: research

Related Links:

(Anesth Analg. 2018;127:1167–1177) Sleep-disordered breathing (SDB) is often comorbid with obesity; among obese pregnant women, 15% to 20% have obstructive sleep apnea (OSA), and prevalence increases with body mass index (BMI). Untreated OSA has been associated with a range of cardiovascular, pulmonary, and metabolic comorbidities. The authors of this review discussed pregnancy as a vulnerable period for the development or worsening of OSA, associations between OSA and adverse maternal and fetal outcomes, current screening modalities for OSA in pregnancy, and current recommendations regarding peripartum management of OSA.
Source: Obstetric Anesthesia Digest - Category: Anesthesiology Tags: Editorials and Reviews Source Type: research
Publication date: May 2019Source: Nano Energy, Volume 59Author(s): He Zhang, Jiwei Zhang, Zhiwei Hu, Liwei Quan, Lin Shi, Jinkai Chen, Weipeng Xuan, Zhicheng Zhang, Shurong Dong, Jikui LuoAbstractObstructive sleep apnea syndrome (OASA) is a respiratory disease caused by upper airway obstruction that is harmful to sleep quality and human health. Real-time monitoring of the respiration status may help to detect the symptoms of apnea and provide accordance to early warning, diagnosis, and proper treatment. As a solution, we here propose a waist-wearable wireless respiration monitoring device based on triboelectric nanogenerat...
Source: Nano Energy - Category: Nanotechnology Source Type: research
Research, published in theEuropean Journal of Endocrinology, suggests that polycystic ovary syndrome may double the risk of obstructive sleep apnea.Healio
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
ConclusionThe use of dexmedetomidine and local anesthetic in pediatric tonsillectomy is a safe and effective protocol that allows for the reduction of opiate use and improved post-operative pain control.Key pointsQuestion: Can the combination of dexmedetomidine and infiltration of local anesthetic reduce overall opioid use for peediatric patients undergoing tonsillectomy?Findings: In this case-control study, use of dexmedetomidine and local anesthetic injected into the tonsillar fossa led to a decrease in intraoperative opiate use by 49.6%, a decrease in intraoperative sevofluorane use by 18%, and a lower reported maximum ...
Source: American Journal of Otolaryngology - Category: Endocrinology Source Type: research
Condition:   Obstructive Sleep Apnea Hypopnea Syndrome Intervention:   Sponsor:   University Hospital, Montpellier Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Obstructive Sleep Apnea Interventions:   Drug: AD036 Dose 1;   Drug: AD036 Dose 2;   Drug: AD036 Dose 3;   Drug: Placebo Sponsor:   Apnimed Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Obstructive Sleep Apnea Hypopnea Syndrome Intervention:   Sponsor:   University Hospital, Montpellier Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Obstructive Sleep Apnea Interventions:   Drug: AD036 Dose 1;   Drug: AD036 Dose 2;   Drug: AD036 Dose 3;   Drug: Placebo Sponsor:   Apnimed Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Obstructive Sleep Apnea Hypopnea Syndrome Intervention:   Sponsor:   University Hospital, Montpellier Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Obstructive Sleep Apnea Interventions:   Drug: AD036 Dose 1;   Drug: AD036 Dose 2;   Drug: AD036 Dose 3;   Drug: Placebo Sponsor:   Apnimed Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Epidemiology | Obstructive Sleep Apnea | Respiratory Medicine | Sleep Disorders | Sleep Medicine | Study